#USA #Actinium-225 #NorthStar #QSA Global #Burlington, Massachusetts; Beloit, Wisconsin

NorthStar and QSA Global Form Strategic Partnership

In a groundbreaking move to enhance cancer treatment options, NorthStar Medical Radioisotopes, a commercial leader in radiopharmaceuticals, has announced a multi-year strategic partnership with QSA Global, Inc., a specialist in radioactive source manufacturing. This alliance is primarily focused on strengthening the supply chain for Actinium-225 (Ac-225), a key isotope used in advanced cancer therapies known as Targeted Alpha Therapies (TAT).

A Closed-Loop Supply Chain

The collaboration takes advantage of NorthStar's capabilities in producing commercial-scale Ac-225 and QSA Global's extensive experience with radioactive isotopes. Specifically, the partnership will optimize the lifecycle management of Radium-226 (Ra-226), which is crucial for the production of Ac-225. The project includes a multi-year purification program, where QSA will process legacy Ra-226 sourced from NorthStar, transforming it into high-purity precursors for continuous target capsule manufacturing.

Once NorthStar irradiates and processes the Ra-226 to generate no-carrier-added (n.c.a) Ac-225, any recovered radium will be returned to QSA Global to be recycled into new targets. This ensures a highly efficient, closed-loop supply chain that will support the increasing demand for effective cancer treatments.

Meeting Industry Demand

Dr. Frank Scholz, President and CEO of NorthStar, emphasized the significance of this partnership. He stated, "This agreement strengthens our supply chain with a reliable, high-quality supply of Ra-226 targets critical to our n.c.a. Ac-225 production capabilities. By ensuring consistent access to these vital starting materials, we can confidently meet growing demand within the industry."

Meanwhile, Dr. Joe Lapinskas, Innovation Director at QSA Global, noted that managing the complex lifecycle of radium-226 will allow NorthStar to concentrate its resources on enhancing Ac-225 production, thereby bolstering the supply chain that supports life-saving TAT applications.

The Promise of Ac-225

Ac-225 is a potent alpha-emitter used for delivering high-energy radiation directly to targeted cancer cells, making it highly advantageous for developing effective radiopharmaceutical therapies. According to NorthStar, Ac-225 can be conjugated with various targeting agents, including antibodies and peptides, to ensure precise delivery to cancerous tissues, which is critical for improving patient outcomes.

This strategic partnership is particularly timely as the demand for advanced cancer therapies continues to rise. As more healthcare providers recognize the potential of isotopes like Ac-225 in targeting hard-to-treat cancers, the importance of a robust supply chain becomes apparent. With this collaboration, NorthStar and QSA Global aim to position themselves as leaders in the field of medical isotopes and targeted therapies.

About QSA Global, Inc.

QSA Global, Inc. has established itself as a pioneer in high-performance radiation sources and equipment. In response to the expanding market for medical radioisotopes, including those used in TAT, the company has enhanced its facilities and expertise in radiochemical processing and regulatory compliance.

About NorthStar Medical Radioisotopes

On the other hand, NorthStar Medical Radioisotopes is recognized for its innovative technologies that lead to the production of essential radioisotopes for treating serious diseases, including cancer. The company is distinguished as the first commercial-scale producer of n.c.a. Ac-225 using electron-accelerator technology. Their commitment to patient-focused therapies makes them a valuable partner in this venture.

As both organizations navigate this new partnership, the implications for cancer treatment could be immense, setting the stage for further advancements in the field of radiopharmaceuticals. Their collaborative efforts not only signal a leap forward for the supply of crucial isotopes but also enhance the potential for developing effective therapies that could dramatically improve patient care.

For more information about NorthStar Medical Radioisotopes and QSA Global, visit their respective websites.